Results 181 to 190 of about 39,011 (251)

Dynamic Changes in Exhaled Breath Glucose by Condensate Collection During Oral Glucose Tolerance Testing in Healthy Adults. [PDF]

Med Devices (Auckl)
Xu W, Zhang Q, Hong Y, Mao Z.
europepmc   +1 more source

Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin‐induced weight gain. Adjunct therapy with modern glucose‐lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis.
Joseph G. Timmons, Husam Ghanim, James G. Boyle, Nicola Greenlaw, Ajay Chaudhuri, Manav A. Batra, Robert S. Lindsay, Lisa Jolly, Caroline Bonner, Alex McConnachie, John R. Petrie, Paresh Dandona   +11 more
wiley   +1 more source

Retraction of: RT McGrath, et al; Evaluation of Blood Glucose Meter Efficacy in an Antenatal Diabetes Clinic. Diabetes Technol Ther. 2016;18(2):68-74. DOI: 10.1089/dia.2015.0104. [PDF]

Diabetes Technol Ther, 2017
europepmc   +1 more source

Continuous Glucose Monitoring and Hypoglycaemia Risk During Paediatric DKA Treatment in the PICU: A Retrospective Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Hypoglycaemia is a frequent complication during diabetic ketoacidosis (DKA) treatment. Continuous glucose monitoring (CGM) provides real‐time glucose trend information; however, its clinical utility during paediatric DKA management in the intensive care unit (ICU) remains uncertain.
Minsun Kim, Esther Park
wiley   +1 more source

Standardized Pipeline for Metabolism and Cognition in GO-DS21 Mouse Model: Investigating Down Syndrome Comorbidities. [PDF]

Curr Protoc
Selloum M, Silva-Buttkus PD, Riet F, Dragano NRV, Garrett L, Jacobs H, Hölter SM, Torquet N, Rathkolb B, Lindner L, Gailus-Durner V, Pavlovic G, Chan L, Beckers J, Demoulière BP, Fuchs H, Ey E, Sorg T, Angelis MH, Herault Y, GO‐DS21 Consortium.   +20 more
europepmc   +1 more source

Effectiveness of Telehealth Low‐Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real‐World, Retrospective, Matched Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Lifestyle interventions targeting metabolic health may influence chronic kidney disease (CKD) risk, particularly among adults with type 2 diabetes and obesity. We evaluated real‐world associations between a telehealth‐delivered, individualized nutrition therapy program (VINT) and CKD incidence and progression compared with usual ...
Shaminie J. Athinarayanan, Petter Bjornstad, Priya V. Shanmugam, Thomas Weimbs, Adam J. Wolfberg, Jeff S. Volek, Jonathan Himmelfarb, Richard J. Johnson   +7 more
wiley   +1 more source

Digital Health Interventions for Type 2 Diabetes: A Narrative Review of Mobile Technologies and Their Impact on Patients' Outcomes. [PDF]

Health Sci Rep
Gohardehi F, Ghanami B, Silakhor M, Sobhanian P.   +3 more
europepmc   +1 more source

Association of Variability of Monthly Continuous Glucose Monitoring‐Derived Metrics With Diabetic Kidney Disease in Type 1 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background While HbA1c is the standard for monitoring long‐term glycaemic control, it fails to capture glycaemic variability. We investigated the discriminatory capacity of longitudinal continuous glucose monitoring (CGM) metrics and identified CGM metric patterns associated with diabetic kidney disease (DKD) in individuals with type 1 ...
Byeongjae Kang, Rosa Oh, Taeyoung Kim, Jee Hee Yoo, Danbee Kang, Gyuri Kim, Sang‐Man Jin, Myung Jin Chung, Jae Hyeon Kim   +8 more
wiley   +1 more source

Evolution and Future of Glucose Monitoring: From Blood Glucose Meters to Continuous Systems and Their Projected Impact in the Middle East and North Africa (MENA) Region. [PDF]

Cureus
Darkhabani O, Ahmed A.
europepmc   +1 more source

Efficacy and Safety of Once‐Weekly Semaglutide 2.0 mg as an Add‐On to Dose‐Reduced Insulin Glargine versus Dose‐Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Type 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once‐weekly semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine (Sema+IGlarreduced) versus dose‐titrated IGlar (IGlartitrated) on glycated haemoglobin (HbA1c), body weight (BW), daily insulin dose, and ...
Helena W. Rodbard, Concetta Irace, Jevitha Lobo, Konstantinos Makrilakis, Prachi Priyadarshini, Suvanjaa Sivalingam, Santiago Tofé Povedano, Anuj Bhargava   +7 more
wiley   +1 more source